Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

    Research output: Contribution to journalReviewResearchpeer-review

  2. Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges

    Research output: Contribution to journalEditorialResearchpeer-review

  3. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Mortality from cardiovascular disease in women with breast cancer - a nationwide registry study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cardiovascular disease in women with breast cancer - a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. HER2-positiv metastatisk brystkræft

    Research output: Contribution to journalReviewResearchpeer-review

  • monarchE Committee Members
View graph of relations

BACKGROUND: Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we present results of the prespecified primary outcome analysis and an additional follow-up analysis.

PATIENTS AND METHODS: This global, phase III, open-label trial randomized (1 : 1) 5637 patients to adjuvant ET for ≥5 years ± abemaciclib for 2 years. Cohort 1 enrolled patients with ≥4 positive axillary lymph nodes (ALNs), or 1-3 positive ALNs and either grade 3 disease or tumor ≥5 cm. Cohort 2 enrolled patients with 1-3 positive ALNs and centrally determined high Ki-67 index (≥20%). The primary endpoint was IDFS in the intent-to-treat population (cohorts 1 and 2). Secondary endpoints were IDFS in patients with high Ki-67, DRFS, overall survival, and safety.

RESULTS: At the primary outcome analysis, with 19 months median follow-up time, abemaciclib + ET resulted in a 29% reduction in the risk of developing an IDFS event [hazard ratio (HR) = 0.71, 95% confidence interval (CI) 0.58-0.87; nominal P = 0.0009]. At the additional follow-up analysis, with 27 months median follow-up and 90% of patients off treatment, IDFS (HR = 0.70, 95% CI 0.59-0.82; nominal P < 0.0001) and DRFS (HR = 0.69, 95% CI 0.57-0.83; nominal P < 0.0001) benefit was maintained. The absolute improvements in 3-year IDFS and DRFS rates were 5.4% and 4.2%, respectively. Whereas Ki-67 index was prognostic, abemaciclib benefit was consistent regardless of Ki-67 index. Safety data were consistent with the known abemaciclib risk profile.

CONCLUSION: Abemaciclib + ET significantly improved IDFS in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer, with an acceptable safety profile. Ki-67 index was prognostic, but abemaciclib benefit was observed regardless of Ki-67 index. Overall, the robust treatment benefit of abemaciclib extended beyond the 2-year treatment period.

Original languageEnglish
JournalAnnals of Oncology
Volume32
Issue number12
Pages (from-to)1571-1581
Number of pages11
ISSN0923-7534
DOIs
Publication statusPublished - Dec 2021

Bibliographical note

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

    Research areas

  • Aminopyridines, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Benzimidazoles, Breast Neoplasms/drug therapy, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Ki-67 Antigen, Neoplasm Recurrence, Local/drug therapy, Receptor, ErbB-2

ID: 70086644